Results 81 to 90 of about 33,582 (263)

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

3152 The role of myostatin in diabetic bone disease

Journal of Clinical and Translational Science, 2019
OBJECTIVES/SPECIFIC AIMS: Our primary objective is to determine the mechanism of action of myostatin on osteoblasts by measuring markers of osteoblast differentiation.
Evangelia Kalaitzoglou, Callie Knuckles, John Fowlkes   +2 more
doaj   +1 more source

Targeting neutrophil extracellular traps in metabolic and immune niche: Nanomaterials for diabetes tissue regeneration

BMEMat, EarlyView.
The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang, Muxin Yue, Kai Mao, Boon Chin Heng, Noor Azlin Yahya, Yunsong Liu, Zheng Li   +6 more
wiley   +1 more source

Plasma and muscle myostatin in relation to type 2 diabetes.

PLoS ONE, 2012
ObjectiveMyostatin is a secreted growth factor expressed in skeletal muscle tissue, which negatively regulates skeletal muscle mass. Recent animal studies suggest a role for myostatin in insulin resistance.
Claus Brandt, Anders R Nielsen, Christian P Fischer, Jakob Hansen, Bente K Pedersen, Peter Plomgaard   +5 more
doaj   +1 more source

Effect of Genetically Reduced Maternal Myostatin on Late Gestation Maternal, Fetal, and Placental Metabolomes in Mice

Metabolites, 2023
Myostatin (gene symbol: Mstn) is an autocrine and paracrine inhibitor of muscle growth. Pregnant mice with genetically reduced levels of myostatin give birth to offspring with greater adult muscle mass and bone biomechanical strength.
Ruth Opoku, Jenna DeCata, Charlotte L. Phillips, Laura C. Schulz   +3 more
doaj   +1 more source

The Myostatin gene: an overview of mechanisms of action and its relevance to livestock animals [PDF]

, 2018
Myostatin, also known as Growth Differentiation Factor 8, a member of the Transforming Growth Factor-beta (TGF-β) super-family is a negative regulator of muscle development.
Amthor, Amthor, Barbaric, Baron, Bellinge, Beyer, Binns, Boman, Boman, Bouyer, Bower, Bryson-Richardson, Cappuccio, Casas, Cash, Chen, Clop, Dall'Olio, Dall'Olio, Dehnavi, Deng, Deveaux, Dunner, Elashry, Esmailizadeh, Fiems, Fontanesi, Georges, Girgenrath, Grisolia, Grobet, Gu, Hadjipavlou, Han, Hanset, Holmes, Hosoyama, Hu, Ji, Jiang, Kambadur, Kijas, Kobolák, Lach-Trifilieff, Langley, Latres, Leymaster, Li, Li, Liu, Lu, Marchitelli, Matsakas, McPherron, Miretti, Mirhoseini, Mosher, Nguluma, Omairi, Ouhayon, Petersen, Pothuraju, Qian, Qiao, Rudnicki, Sarti, Sazanov, Schuelke, Sellick, Sjakste, Stefaniuk, Stefaniuk, Sternstein, Stinckens, Thomas, Tozaki, Trendelenburg, Trukhachev, Vankan, Vincenti, Wang, Wang, Wegner, Wiener, Wolfman, Xu, Ye, Zhang, Zhang, Zhang, Zhao, Zhiliang, Zhou, Zou   +93 more
core   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Roles of mechanistic target of rapamycin and transforming growth factor-B signaling in the molting gland (Y-organ) of the blackback land crab, Gecarcinus lateralis [PDF]

, 2016
Molting in decapod crustaceans is controlled by molt-inhibiting hormone (MIH), an eyestalk neuropeptide that suppresses production of ecdysteroids by a pair of molting glands (Y-organs or YOs). Eyestalk ablation (ESA) activates the YOs, which hypertrophy
Abuhagr, Ali M., Chang, Ernest S., Chang, Sharon A., MacLea, Kyle S., Mudron, Megan R., Mykles, Donald L.   +5 more
core   +2 more sources

Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?

Journal of Bone Metabolism, 2020
Myostatin, also known as growth differentiation factor 8 (GDF8), is a transforming growth factor-β (TGF-β) family member that functions to limit skeletal muscle growth. Accordingly, loss-of-function mutations in myostatin result in a dramatic increase in
Joonho Suh, Yun‐Sil Lee
semanticscholar   +1 more source

Myostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification

Cells, 2021
A current hypothesis is that transforming growth factor-β signaling ligands, such as activin-A and myostatin, play a role in vascular damage in atherosclerosis and chronic kidney disease (CKD).
P. Esposito, D. Verzola, D. Picciotto, L. Cipriani, F. Viazzi, G. Garibotto   +5 more
semanticscholar   +1 more source